Ziresovir reduces respiratory syncytial virus (RSV) symptoms and viral load in infants, offering hope for an effective ...

Significantly greater reduction from baseline seen in Wang bronchiolitis clinical score at day 3 for those aged 1 to 24 months ...

Overall, 55.8% of infants were protected by either maternal RSV vaccination, nirsevimab, or both; 14.2% of infants were ...

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio"), a clinical stage biopharmaceutical company focused on the development of ...

Current strategies to prevent severe RSV disease in infants include maternal vaccination with the RSV prefusion F vaccine ...

Results of a phase 2 trial suggested that ziresovir may have efficacy in the treatment of infants hospitalized with RSV infection. In a phase 3, multicenter, double-blind, randomized, placebo ...

China: In a promising development for pediatric care, a recent study has highlighted the efficacy of Ziresovir in treating ...

and the only available treatment, aerosolized ribavirin, has low efficacy. Ziresovir may offer a new treatment option. New research findings are summarized in a short video.

For infants and young children hospitalized with respiratory syncytial virus (RSV) infection, ziresovir reduces signs and symptoms of bronchiolitis, according to a study published in the Sept.